Average Co-Inventor Count = 3.69
ph-index = 8
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Dana-Farber-Cancer Institute Inc. (17 from 1,211 patents)
2. Proxygen Gmbh (1 from 1 patent)
3. Cemm Forschungszentrum Fur Molekulare Medizin Gmbh (10 patents)
18 patents:
1. 12410152 - Oxazole and thioazole-type cullin ring ubiquitin ligase compounds and uses thereof
2. 12023385 - Tunable endogenous protein degradation with heterobifunctional compounds
3. 11583586 - Methods to induce targeted protein degradation through bifunctional molecules
4. 11578075 - Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use
5. 11311609 - Regulating chimeric antigen receptors
6. 11293023 - Tunable endogenous protein degradation
7. 11059801 - Methods to induce targeted protein degradation through bifunctional molecules
8. 11046954 - Targeted protein degradation to attenuate adoptive T-cell therapy associated adverse inflammatory responses
9. 10925868 - Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use
10. 10899768 - Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use
11. 10849980 - Methods to induce targeted protein degradation through bifunctional molecules
12. 10669253 - Methods to induce targeted protein degradation through bifunctional molecules
13. 10464925 - Methods to induce targeted protein degradation through bifunctional molecules
14. 10125114 - Methods to induce targeted protein degradation through bifunctional molecules
15. 9821068 - Methods to induce targeted protein degradation through bifunctional molecules